AllianceBernstein’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

AllianceBernstein’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,300	Closed	-$52K	–	3499
2021 Q1	$52K	Sell	15,300 -2,500	-14%	-$47.3K	﹤0.01%	3194
2020 Q4	$342K	Buy	+17,800	New	+$275K	﹤0.01%	2798
2020 Q3	–	Sell	-15,100	Closed	-$639K	–	3235
2020 Q2	$639K	Sell	15,100 -500	-3%	-$16.2K	﹤0.01%	2453
2020 Q1	$431K	Sell	15,600 -2,000	-11%	-$58.3K	﹤0.01%	2424
2019 Q4	$571K	Buy	17,600 +2,100	+14%	+$65.1K	﹤0.01%	2491
2019 Q3	$403K	Buy	15,500 +1,900	+14%	+$63.6K	﹤0.01%	2664
2019 Q2	$499K	Buy	13,600 +3,800	+39%	+$91.1K	﹤0.01%	2601
2019 Q1	$217K	Buy	+9,800	New	+$171K	﹤0.01%	2883

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AllianceBernstein's ODT Position: Q2 2021 in Review

AllianceBernstein sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2021, closing a stake of 15,300 shares — an estimated $52K sold.

AllianceBernstein first reported a position in ODT in Q1 2019 and held it in 8 quarters. The position peaked at $639K in Q2 2020. 69 funds tracked by Wall St. Rank hold ODT as of Q2 2021.

AllianceBernstein reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 15,300 Odonate Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $52K.
AllianceBernstein first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2019 and held it in 8 quarters.
AllianceBernstein's Odonate Therapeutics, Inc. Common Stock position peaked at $639K in Q2 2020.
69 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.